Psyence Biomedical PBM 深 滬
等待開盤 11-04 09:30:00 美东时间
3.29
+0.110
+3.46%
華盛通- 最 高3.50
- 今 開3.18
- 成交量 5.50万股
- 最 低 3.11
- 昨 收 3.18
- 總市值 1254.91万
- 52周最高 26.1719
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 1.92
- 委 比 -37.50%
- 總股本 381.43万
- 歷史最高 16101.8902
- 量 比 0.55
- 振 幅 12.26%
- 歷史最低 1.92
- 每 手 1
- 風險率 3.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Psyence Biomedical Completes Its Additional Investment In PsyLabs Of $2,599,896
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd. ("PsyLabs") have been achieved and that the Company, through its wholly-owned subsidiary Psyence Biomed II Corp., has co...
10-21 19:06
Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient
Benuvia operates an 83,000-square-foot, DEA-registered controlled-substance manufacturing facility in Round Rock, Texas, with capabilities spanning development through commercial-scale production Partnership is intended to connect TIRC’s planned exclusive U.S. access to PsyLabs’ pharmaceutical-grade...
10-05 19:06
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Psyence BioMed's Texas subsidiary, TIRC, has signed a binding term sheet with PsyLabs granting exclusive U.S. rights to develop, supply, and distribute PsyLabs' pharmaceutical-grade ibogaine. The agreement includes an exclusive license, supply, and distribution arrangement, with TIRC paying up to $1.3 million in milestones, an annual exclusivity fee, and royalties. PsyLabs retains rights outside the U.S. The term sheet is subject to a definitive ...
09-28 11:00
Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD). Texas Ibogaine Research Corporation (T...
09-23 19:02
Psyence BioMed Announces Strategic Ibogaine Investment
Psyence BioMed has agreed to invest up to $5 million in PsyLabs and exchange shares worth approximately $9 million each to support the development of a U.S. ibogaine program for Opioid Use Disorder. A subsidiary, TIRC, has been established in Texas to coordinate regulatory and clinical activities. The investment and share exchange aim to align the companies' resources for clinical research and manufacturing.
09-23 11:00
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Psyence Biomedical Ltd. has established Texas Ibogaine Research Corporation (TIRC) to coordinate U.S. ibogaine development, supply, and clinical activities. TIRC will hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, with plans to engage in regulatory and clinical development. Jody Aufrichtig leads TIRC, aiming to advance research and development for U.S. patients.
09-14 11:00
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed Ltd. welcomed President Trump's announcement supporting the accelerated development of ibogaine as a potential medical treatment in the U.S. The company, which specializes in nature-derived psychedelic compounds, holds a significant stake in PsyLabs, a GMP-compliant manufacturer of ibogaine hydrochloride. Psyence BioMed is positioned to contribute to the regulated clinical development of ibogaine, aligning with the federal governme...
08-18 21:23
美股夜盘 | 柏雅国际涨41.30%，Advanced Biomed涨31.21%
Digital Brands Group, Inc.涨-20.24%；Ryde Group涨-12.83%；Psyence Biomedical Ltd.涨-9.12%
07-20 08:05
